Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Ginevra, Fiori"'
Autor:
Cosimo Bruni, Cosimo Cigolini, Giulia Tesei, Laura Cometi, Francesca Bartoli, Ginevra Fiori, Francesca Nacci, Silvia Bellando-Randone, Serena Guiducci, Marco Matucci-Cerinic
Publikováno v:
European Journal of Rheumatology, Vol 8, Iss 4, Pp 190-195 (2021)
Externí odkaz:
https://doaj.org/article/f80be4e28ec645649f0ff644ea8d4d44
Autor:
Cosimo Bruni, Stefano Gentileschi, Giovanni Pacini, Marco Bardelli, Lorenzo Tofani, Francesca Bartoli, Caterina Baldi, Laura Cometi, Ginevra Fiori, Francesca Nacci, Luca Cantarini, Serena Guiducci, Alberto Moggi-Pignone, Bruno Frediani, Marco Matucci-Cerinic
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)
Aims: Medical and non-medical switching strategies have been adopted in Europe in the last few years. We aimed to investigate persistence on treatment with a SB5 Adalimumab (SB5) biosimilar after switching from Adalimumab (ADA) originator among patie
Externí odkaz:
https://doaj.org/article/c82ec4d5c5804403a16b1317eb025061
Autor:
Giulia Tesei, Laura Cometi, Francesca Nacci, Riccardo Terenzi, Lorenzo Tofani, Marco Capassoni, Francesca Bartoli, Ginevra Fiori, Marco Matucci-Cerinic, Cosimo Bruni
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)
Background: Ultrasound (US) is useful in monitoring RA patients, with the US7 score allowing grey-scale and power-Doppler (PD) semi-quantitative evaluation of synovitis and teno-synovitis. We evaluated real-life efficacy and safety of Baricitinib, an
Externí odkaz:
https://doaj.org/article/e51503846e3e41a1acac156a1e1f23c3
Autor:
Cosimo Bruni, Stefano Gentileschi, Giovanni Pacini, Caterina Baldi, Marco Capassoni, Lorenzo Tofani, Marco Bardelli, Laura Cometi, Luca Cantarini, Francesca Nacci, Michele Vietri, Francesca Bartoli, Ginevra Fiori, Bruno Frediani, Marco Matucci-Cerinic
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 12 (2020)
Aims: Switching from originator to biosimilar is part of current practice in inflammatory rheumatic musculoskeletal diseases (iRMDs) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondylarthritis (axSpA), with evidences deriv
Externí odkaz:
https://doaj.org/article/c897c72d48d5467880eaf49ed3edc699
Autor:
Laura Cometi, Maria Letizia Conforti, Martina Orlandi, Khadija El Aoufy, Laura Rasero, Francesca Bartoli, Francesca Nacci, Jelena Blagojevic, Serena Guiducci, Alberto Moggi-Pignone, Marco Matucci-Cerinic, Maria Ramona Melis, Ginevra Fiori, Cosimo Bruni, Silvia Bellando Randone
Publikováno v:
Clinical Rheumatology
Patients and health workers were at high risk of infection during the Sars-Cov-2 pandemic lockdown. For this reason, other medical and clinical approaches such as Telemedicine were necessary. Despite Telemedicine was born before COVID-19, the pandemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c11e61b9afdd3083bbbe59384815c357
http://europepmc.org/articles/PMC8569841
http://europepmc.org/articles/PMC8569841
Autor:
Arianna, Damiani, Francesca, Bartoli, Giovanni, Pacini, Davide, Carboni, Silvia, Bellando Randone, Ginevra, Fiori, Marco, Matucci-Cerinic, Serena, Guiducci
Publikováno v:
Clinical and Experimental Rheumatology.
In refractory inflammatory joint diseases (IJDs) biological disease-modifying anti-rheumatic drugs (bDMARDs) may achieve remission. EULAR recommends bDMARD tapering when remission persists. However, guidelines on tapering modalities and criteria for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90e94e388d0b2159eb6459c582d59e64
https://doi.org/10.55563/clinexprheumatol/k76z51
https://doi.org/10.55563/clinexprheumatol/k76z51
Autor:
C. Bruni, Laura Cometi, Francesca Bartoli, Ginevra Fiori, M. Matucci-Cerinic, Francesca Nacci, Giulia Tesei, Lorenzo Tofani
Publikováno v:
Annals of the Rheumatic Diseases. 80:1154-1155
Background:Biologic and target synthetic disease modifying anti-rheumatic drugs (bDMARDs and tcDMARDs) are recommended to control RA disease activity, pain and steroid use. Following randomized clinical trials (RCTs) and their post-hoc analyses, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e92111fc28082dfb89681a44033a7119
https://doi.org/10.1136/annrheumdis-2021-eular.1343
https://doi.org/10.1136/annrheumdis-2021-eular.1343
Autor:
Cosimo Bruni, Lorenzo Tofani, Riccardo Terenzi, Francesca Bartoli, Francesca Nacci, Marco Matucci-Cerinic, Ginevra Fiori, Marco Capassoni, Laura Cometi, Giulia Tesei
Publikováno v:
Annals of the Rheumatic Diseases. 79:1481-1482
Background:Remission or low disease activity (LDA) are the ultimate goals of both conventional synthetic (csDMARD), target synthetic and biologic disease-modifying anti-rheumatic drugs (bDMARD) in treating RA. Janus Kinase (JAK) inhibitors are nowada
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efadc64dde2c8717e24475ca0ca4d8a6
https://doi.org/10.1136/annrheumdis-2020-eular.1954
https://doi.org/10.1136/annrheumdis-2020-eular.1954
Autor:
Silvia Bellando Randone, Cosimo Cigolini, Giulia Tesei, Cosimo Bruni, Serena Guiducci, Maria Letizia Conforti, Marco Matucci-Cerinic, Ginevra Fiori, Francesca Bartoli
Publikováno v:
Abstracts Accepted for Publication.
Background Osteoporosis is a frequent complication of rheumatic muscle-skeletal diseases (RMD), with high impact from steroid treatment. It is known that bDMARD impact positively on patients’ prognosis and this is also known for Denosumab, a monocl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ec3e83e3d78c3b778efe4df1529eb5d
https://doi.org/10.1136/annrheumdis-2019-eular.3505
https://doi.org/10.1136/annrheumdis-2019-eular.3505
Autor:
Michele Vietri, Francesca Bartoli, Marco Matucci-Cerinic, Bruno Frediani, Ginevra Fiori, Cosimo Bruni, Laura Cometi, Lorenzo Tofani, Caterina Baldi, Marco Bardelli, Giovanni Pacini, Marco Capassoni, Francesca Nacci, Stefano Gentileschi, Luca Cantarini
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease
Therapeutic Advances in Musculoskeletal Disease, Vol 12 (2020)
Therapeutic Advances in Musculoskeletal Disease, Vol 12 (2020)
Aims: Switching from originator to biosimilar is part of current practice in inflammatory rheumatic musculoskeletal diseases (iRMDs) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondylarthritis (axSpA), with evidences deriv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38256a488bd390de082a94ebf5ec8886
http://europepmc.org/articles/PMC7576915
http://europepmc.org/articles/PMC7576915